Linker Modification for Radioimmunoconjugate Metabolite Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radioimmunoconjugates face challenges in efficiently eliminating radioactivity from the body after catabolism, leading to prolonged body burden and potential off-target toxicity, despite efforts to maintain target affinity and pharmacokinetics.
Innovation Solution
Modifying the linker region of bifunctional chelates to enhance the excretion of chelating moieties or metal complexes when conjugated to therapeutic or targeting moieties, thereby increasing the clearance of radioactive metabolites without affecting the in vivo properties of the intact radioimmunoconjugate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the linker region of bifunctional chelates is modified to enhance excretion of chelating moieties, then the clearance of radioactive metabolites is improved, but the complexity of the chelate structure increases
Solution Approach 1:
The bifunctional chelate is divided into distinct functional segments: a chelating moiety (e.g., DOTA, NOTA) for metal ion coordination, a modified linker region with enhanced hydrophilicity (containing polar groups like carboxylates, hydroxyls, or amides), and a targeting/therapeutic moiety. This segmentation allows each component to independently fulfill its function while the hydrophilic linker specifically enhances renal excretion of catabolic products without interfering with target binding or chelation stability.
2Object-affected harmful factors
If the excretion of chelating moieties is enhanced through linker modification, then off-target toxicity is reduced, but the manufacturing complexity increases
Solution Approach 1:
The linker region is chemically modified by introducing polar functional groups (carboxylates, hydroxyls, amides) or polyethylene glycol chains to increase hydrophilicity. This parameter change in the linker's physical-chemical properties enhances the water solubility and renal clearance of chelate catabolic products, reducing off-target radiation exposure. The modifications are implemented through established conjugation chemistry that maintains compatibility with standard radioimmunoconjugate manufacturing workflows.
3Duration of action of moving object
If the linker region is modified to increase clearance of radioactivity, then the pharmacokinetic profile is improved, but the structural complexity of the bifunctional chelate increases
Solution Approach 1:
The modified linker acts as an intermediary component between the chelating moiety and the targeting/therapeutic moiety. By incorporating hydrophilic groups or polyethylene glycol chains into the linker, the invention mediates enhanced renal excretion of chelate fragments without disrupting the target-binding properties of the antibody or peptide and without compromising the stability of the metal-chelate complex. This intermediary approach allows independent optimization of each functional region.
Data Source
AI summary
The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof.